• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

University Hospital Ulm uses an innovative educational system by EBS for education in dentistry

, Medizintechnik, EBS Euchner Büro- und Schulsysteme GmbH

EBS, manufacturer of multimedia training solutions, has equipped the University Hospital Ulm with an innovative system for training students...

i-cor®: Das erste Kreislaufunterstützungssystem, das synchron mit dem Herzen pumpt

, Medizintechnik, Xenios AG

Die Xenios AG, Heilbronn, bietet mit der i-cor® zum ersten Mal ein extrakorporales Verfahren speziell für die interventionelle Kardiologie an....

Synchronisierter Puls revolutioniert die Behandlung des akuten Pumpversagens des Herzens

, Medizintechnik, Xenios AG

Die Xenios AG, Heilbronn, bietet mit der i-cor® eine Weltneuheit zur Herzunterstützung an und stellt zum Auftakt der 80. Jahresversammlung der...

Disclaimer